Nuvation Bio Secures FDA sNDA Approval for IBTROZI® (Taletrectinib) – Updated Label Reports Longest Median DOR Among Approved ROS1 TKIs in TKI‑Naïve ROS1‑Positive NSCLC
Others

Nuvation Bio Secures FDA sNDA Approval for IBTROZI® (Taletrectinib) – Updated Label Reports Longest Median DOR Among Approved ROS1 TKIs in TKI‑Naïve ROS1‑Positive NSCLC

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on some of the most formidable challenges in cancer treatment, announced that the U.S. Food and Drug Administration (FDA) has…

MIIT and Nine Departments Issue China's "15th Five‑Year Plan for Pharmaceutical Industry Development" – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030
Policy / Regulatory

MIIT and Nine Departments Issue China’s “15th Five‑Year Plan for Pharmaceutical Industry Development” – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030

Roche Opens Genentech Innovation Center Boston at Harvard's Enterprise Research Campus – New US Hub for Cardiovascular, Renal and Metabolism R&D
Company

Roche Opens Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus – New US Hub for Cardiovascular, Renal and Metabolism R&D

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World's First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development
CompanyDeals

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World’s First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status
CompanyDeals

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status

- Advertisement -
Ad image
Eli Lilly's Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL/SLL Trial – Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History
CompanyDrug

Eli Lilly’s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL/SLL Trial – Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History

Sanofi Secures EC Approval for Dupixent in Pediatric Chronic Spontaneous Urticaria – First Biologic Therapy for Children 2–11 Years
CompanyDrug

Sanofi Secures EC Approval for Dupixent in Pediatric Chronic Spontaneous Urticaria – First Biologic Therapy for Children 2–11 Years

AstraZeneca's Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data
CompanyDrug

AstraZeneca’s Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data

RemeGen's Disitamab Vedotin Wins World's First HER2-ADC Approval for First-Line Advanced Urothelial Carcinoma
CompanyDrug

RemeGen’s Disitamab Vedotin Wins World’s First HER2-ADC Approval for First-Line Advanced Urothelial Carcinoma

CompanyDrug

Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche’s Phesgo

AbbVie Secures NMPA Label Expansion for Rinvoq in China, Clarifying Use in UC and Crohn's Disease
CompanyDrug

AbbVie Secures NMPA Label Expansion for Rinvoq in China, Clarifying Use in UC and Crohn’s Disease

CompanyDeals

IASO Biotherapeutics Partners with Brazil’s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers

CanSino Biologics Secures NMPA Approval for Pankangxin, China's First Three-Component Acellular DTaP Vaccine
CompanyDrug

CanSino Biologics Secures NMPA Approval for Pankangxin, China’s First Three-Component Acellular DTaP Vaccine

CompanyDeals

Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value

CompanyDrug

Cutia Therapeutics’ CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines

CompanyDrug

Hotgen Biotech’s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle

CompanyDeals

Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights

Show More